Sareum Holdings plc (SAR.L)
- Previous Close
35.00 - Open
0.00 - Bid 39.00 x --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 142.00 - Volume
854,634 - Avg. Volume
1,705,293 - Market Cap (intraday)
43.178M - Beta (5Y Monthly) -1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.06 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
176.00
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
www.sareum.comRecent News: SAR.L
Performance Overview: SAR.L
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAR.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAR.L
Valuation Measures
Market Cap
43.18M
Enterprise Value
42.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
90.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-113.80%
Return on Equity (ttm)
-257.72%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.25M
Diluted EPS (ttm)
-0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
408k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.6M